Indian Immunologicals Ltd (IIL) has set up a facility in Hyderabad with an investment of Rs.250 crore to manufacture vaccines against infectious diseases of humans and animal health formulations.
Spread on 47 acres, at Phase III of Genome Valley in Karkapatla, Ranga Reddy District, it will help significantly expand the manufacturing capabilities, the company announced on Monday. The facility, IIL’s second in Hyderabad, would cater to domestic as well as international markets.
The first phase of human vaccine facility can produce 8 million doses of human rabies vaccine. The animal health formulation facility is equipped to produce an estimated capacity of 300 million tablets, 100 million bolus, and 20 million vials of injectables. Stating this, a release from the company said that the facility has been developed keeping in mind the growing demand for the next 10 years for human vaccines and animal health formulations.
The new facility, which will become India’s largest for producing animal health formulations, is equipped to manufacture rabies vaccine for humans and produces new animal health formulations for bovines, sheep and pets. It will provide direct employment to 150 and indirect employment to 300 people.
Deputy Managing Director K. Anand Kumar said: “The facility will strengthen IIL’s position in the industry and immensely increase our manufacturing capabilities. We are expecting this plant to play a key role in manufacturing top quality vaccines with the most recent German technology.”
With the opening of the plant, IIL has five manufacturing facilities -- anti rabies production unit in Ooty, Tamil Nadu; Cattle feed Unit in Rajkot, Gujarat; biologicals unit in Gachibowli, Hyderabad; and serum manufacturing unit in New Zealand.
